GoldBamboo.com - Knowledge is strong medicine
  

Genetic Determinants of Warfarin Anticoagulation Effect - Article


  Not Signed In - Sign In / Register






Warfarin

Coumadin; Jantoven


Clinical Trial: Genetic Determinants of Warfarin Anticoagulation Effect

This study is currently recruiting patients.
Verified by Hadassah Medical Organization August 2004

Sponsors and Collaborators: Hadassah Medical Organization
United States - Israel Binational Science Foundation
Israel Science Foundation
Chief scientist, Israeli Ministry of Health
Information provided by: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00162435

Purpose

The response to warfarin varies greatly among individuals. Some of this variability can be ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the metabolism of S warfarin. The present study has several segments:

  1. Evaluation of the relationship between CYP2C9 genetic polymorphisms warfarin maintenance dose at steady state (completed). This study is a confirmation of previous data in our own population.
  2. Testing the hypothesis that warfarin loading based on the individual''''s CYP2C9 genotype may be more efficient and associated with reduced adverse drug effects.
Condition Intervention
Venous Thrombosis
Pulmonary Embolism
Atrial Fibrillation
 Drug: Warfarin

MedlinePlus related topics:  Arrhythmia;   Pulmonary Embolism;   Thrombophlebitis

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Pharmacokinetics/Dynamics Study

Official Title: Warfarin Induction Regimen Based Upon CYP2C9 Genotyping and INR Monitoring, as Compared to the Conventional Regimen: a Prospective Controlled Study

Further Study Details: 
Primary Outcomes: Pharmacokinetic end points:; 1. Warfarin clearance and formation clearance of 7-hydroxy-warfarin at steady state; Pharmacodynamic; 1. Maintenance dose of warfarin at steady state; 2. Time to reach INR > 2; 3. Time to reach pharmacodynamic steady state; 4. Time spent at therapeutic INR <3 and >2.; 5. Time spent at INR >3; 6. Time spent at INR <2; 7. The incidence of minor and major bleeding episodes
Expected Total Enrollment:  400

Study start: August 2002

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

Exclusion Criteria:

  • Refusal to participate in the study

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00162435

Yoseph Caraco, MD      00 972 2 6778584    caraco@hadassah.org.il

Israel
      Hadassah Medical Organization, Jerusalem,  Israel; Recruiting
Arik Tzukert, DMD  00 972 2 6776095    arik@hadassah.org.il 
Hadas Lemberg, PhD  00 972 2 6777572    lhadas@hadassah.org.il 
Yoseph Caraco, MD,  Principal Investigator

Study chairs or principal investigators

Yoseph Caraco, MD,  Principal Investigator,  Hadassah Medical Organization   

More Information

Study ID Numbers:  22-15/06/01
Last Updated:  September 12, 2005
Record first received:  September 11, 2005
ClinicalTrials.gov Identifier:  NCT00162435
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2005-09-13


Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $50 a year, a savings of 50% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Warfarin.

September 7, 2008



Page Updated: October 3, 2005
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Insurance Quotes | Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Google Co-op | Health Forums

Copyright © 2004-2008 - Gold Bamboo LLC
All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.